More about parkinsonism after taking ecstasy.
Sewell
R A
RA
Cozzi
N V
NV
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000009:adverse effects*; D001479:Basal Ganglia / Q000187:drug effects; D015259:Dopamine Agents / Q000009:adverse effects*; D006213:Hallucinogens / Q000009:adverse effects*; D006801:Humans; D013287:Illicit Drugs / Q000737:chemistry; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000009:adverse effects*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced*
D015259:Dopamine Agents; D006213:Hallucinogens; D013287:Illicit Drugs; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D018817:N-Methyl-3,4-methylenedioxyamphetamine